Primary objective:
To improve rates of complete remission (CR) in HR ALL relapse patients.
Secondary objectives:
Improve rates of event-free survival (EFS) and overall survival (OS)
Improvement in MRD reduction after induction with versus without bortezomib
Evaluation of the toxicity of induction with versus without bortezomib
Evaluation of the efficacy of the consolidation elements with regard to reducing the MRD burden until
to allo-HSCT
